Mizuho raised the firm’s price target on Alkermes (ALKS) to $40 from $35 and keeps an Outperform rating on the shares. The firm assessed ...

BofA raised the firm’s price target on Alkermes (ALKS) to $31 from $28 and keeps a Neutral rating on the shares, citing a higher multiple given the recent move in biotech peer comps for the increased ...

Stifel has upgraded Alkermes (NASDAQ:ALKS) to buy from hold, citing increased confidence in the company’s narcolepsy drug ...

Alkermes (NASDAQ:ALKS – Get Free Report) had its target price dropped by equities researchers at The Goldman Sachs Group from ...

Alkermes is a biopharmaceutical company primarily involved in developing treatments for central nervous system disorders. Its current lineup includes schizophrenia treatment Aristada ...

Alkermes (NASDAQ:ALKS – Free Report) had its price target lowered by Cantor Fitzgerald from $48.00 to $43.00 in a research ...

Cantor Fitzgerald lowered the firm’s price target on Alkermes (ALKS) to $43 from $48 and keeps an Overweight rating on the shares. Alkermes reported Q3 revenues below consensus estimates but in ...

Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Greetings and welcome to the Alkermes' Third Quarter 2024 Financial Results Conference Call. My name is Maria and I'll be your operator for today's call. All participant lines will be placed on ...

Alkermes (ALKS) came out with quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.78 per share. This compares to earnings of $0.64 per share a year ago. These figures ...

DUBLIN (AP) — DUBLIN (AP) — Alkermes PLC (ALKS) on Thursday reported third-quarter profit of $92.4 million. On a per-share basis, the Dublin-based company said it had profit of 55 cents.